Is Neuroblastoma A Case of Viral Mimicry Suppression?

Ugo Rovigatti

doi:10.53941/ti.2026.100024

Abstract

Generalization and paradigms in Cancer Research are useful but easily lead to conundrums, confusion or paradoxes, as shown here by contraposing two generally accepted “keywords” such as “Targeted Gene Theray” (TGT) and “Viral Mimicry” (VM). The initial approach to oncogene abnormalities was epitomized by the 1989 Weinberg’s paper: “throwing monkey wrenches into the clock”: although we now throw smart small and efficacious molecules, the general approach has not changed. It was believed that curing the gene would cure the disease and nobody asked why such mutations appeared in the first place. We realize today that TGTs are short-lasting. Recently, several groups, working on adult cancers, emphasized the new concept of Viral Mimicry (VM), which sheds new light on the origin of oncogene mutations. Accordingly, oncogene mutations appear as strong suppressors of VM programs: inactivating mutated oncogenes permits the full-blown apoptotic VM program to take place. Initial VM activation is believed to be predominantly associated with dsRNA of Endogenous Elements (EE), but other types of daRNAs have been described. In Neuroblastoma -where VM has been practically ignored- we discovered and isolated a dsRNA virus (MFV) associated with VM death and activation of dsRNA helicases, which is counteracted by DNA amplification of the MYCN proto-oncogene. It is therefore suggested that further research on VM should be extended also to pediatric cancers and especially Neuroblastoma, since it provides a logic explanation for the Darwinian forces, which select for and determine the otherwise unexplainable MYCN amplifications phenomena.

References

1.
Rovigatti, U. Cancer modelling in the NGS era—Part I: Emerging technology and initial modelling. Crit. Rev. Oncol. Hematol. 2015, 96, 274–307. https://doi.org/10.1016/j.critrevonc.2015.05.017.
2.
Rovigatti, U.G. The Long Journey of Cancer Modeling: Ubi Sumus? Quo Vadimus? Mathews J. Cancer Sci. 2016, 1, 1–5.
3.
Rovigatti, U.; Papaioannou, G.; Mammas, I.N.; et al. Neuroblastoma in childhood and its potential viral involvement: A webinar by the Paediatric Virology Study Group. World Acad. Sci. J. 2022, 4, 16 ST.
4.
Lees, J.A.; Weinberg, R.A. Tossing monkey wrenches into the clock: New ways of treating cancer. Proc. Natl. Acad. Sci. USA 1999, 96, 4221–4223. https://doi.org/10.1073/pnas.96.8.4221.
5.
Wagle, N.; Emery, C.; Berger, M.F.; et al. Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. J. Clin. Oncol. 2011, 29, 3085–3096. https://doi.org/10.1200/jco.2010.33.2312.
6.
Gerlinger, M.; Swanton, C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 2010, 103, 1139–1143. https://doi.org/10.1038/sj.bjc.6605912.
7.
Fletcher, J.I.; Ziegler, D.S.; Trahair, T.N.; et al. Too many targets, not enough patients: Rethinking neuroblastoma clinical trials. Nat. Rev. Cancer 2018, 18, 389–400. https://doi.org/10.1038/s41568-018-0003-x.
8.
Rovigatti, U. Isolation and initial characterization of a new virus: Micro-Foci inducing virus or MFV. C R Acad Sci III 1992, 315, 195–202.
9.
Rovigatti, U. The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL). Cancer Lett. 2021, 503, 220–230. https://doi.org/10.1016/j.canlet.2020.11.044.
10.
Gatenby, R.A.; Gillies, R.J.; Brown, J.S. Of cancer and cave fish. Nat. Rev. Cancer 2011, 11, 237–238. https://doi.org/10.1038/nrc3036.
11.
Maley, C.C.; Aktipis, A.; Graham, T.A.; et al. Classifying the evolutionary and ecological features of neoplasms. Nat. Rev. Cancer 2017, 17, 605–619. https://doi.org/10.1038/nrc.2017.69.
12.
Gatenby, R. Cancer biology and Mr. Darwin. Biochim. et Biophys. Acta BBA-Rev. Cancer 2017, 1867, 67–68. https://doi.org/10.1016/j.bbcan.2017.04.003.
13.
Gatenby, R.A. The Approaching Darwinian Era in Oncology. Cancer Res. 2025, 85, 3373–3375. https://doi.org/10.1158/0008-5472.can-25-1878.
14.
Rovigatti, U.; Piccin, A.; Colognato, R.; et al. Preliminary Characterization of a New Type of Viruses Isolated from Paediatric Neuroblastoma and Non-Hodgkin’s Lymphoma: potential Implications for Aetiology. In Proceedings of the International Conference on Childhood Leukaemia, London, UK, 6–10 September 2004; pp. P1–18 pp. I–IV.
15.
Rovigatti, U. Chronic Fatigue Syndrome (CFS) and Cancer Related Fatigue (CRF): Two “fatigue” syndromes with overlapping symptoms and possibly related aetiologies. Neuromuscul. Disord. 2012, 22, S235–S241. https://doi.org/10.1016/j.nmd.2012.10.018.
16.
Zhou, Y.; Zhang, Y.; Li, M.; et al. Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry. Sci. Immunol. 2024, 9, eado8758. https://doi.org/10.1126/sciimmunol.ado8758.
17.
Rovigatti, U.G.; Astrin, S.M. Avian endogenous viral genes. Curr. Top Microbiol. Immunol. 1983, 103, 1–21.
18.
Belancio, V.P.; Roy-Engel, A.M.; Deininger, P.L. All y’all need to know ‘bout retroelements in cancer’. Semin. Cancer Biol. 2010, 20, 200–210. https://doi.org/10.1016/j.semcancer.2010.06.001.
19.
Milcarek, A.T.; Yeon, M.; Esposito, C.; et al. Mitochondrial double-stranded RNA fuels pancreatic cancer growth via RIG-I/TLR3 inflammation. Proc. Natl. Acad. Sci. USA 2026, 123, e2528281123. https://doi.org/10.1073/pnas.2528281123.
20.
Liao, W.; Overman, M.J.; Boutin, A.T.; et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell 2019, 35, 559–572.e7. https://doi.org/10.1016/j.ccell.2019.02.008.
21.
Levine, M.S.; Li, J.; Ehrlich, L.I.R.; et al. Viral mimicry may help explain immunogenic cell death. Proc. Natl. Acad. Sci. USA 2026, 123, e2537547123. https://doi.org/10.1073/pnas.2537547123.
22.
Chen, R.; He, A.; De Carvalho, D.D. Viral mimicry evasion: A new role for oncogenic KRAS mutations. Mol. Oncol. 2025, 19, 271–274. https://doi.org/10.1002/1878-0261.13771.
23.
Chen, R.; He, A.; Lindholm, H.T.; et al. Viral mimicry escape as a necessary feature of malignant transformation. Nat. Rev. Cancer 2026. https://doi.org/10.1038/s41568-026-00977-1.
24.
Rovigatti, U. “THE ENDS IN THE BEGINNINGS” age-related mechanisms of Telomere maintenance in pediatric and AYA-group Neuroblastoma. Crit. Rev. Oncol. Hematol. 2026, 218, 105047. https://doi.org/10.1016/j.critrevonc.2025.105047.
25.
Gundem, G.; Levine, M.F.; Roberts, S.S.; et al. Clonal evolution during metastatic spread in high-risk neuroblastoma. Nat. Genet. 2023, 55, 1022–1033. https://doi.org/10.1038/s41588-023-01395-x.
26.
Raitio, A.; Rice, M.J.; Mullassery, D.; et al. Stage 4S Neuroblastoma: What Are the Outcomes? A Systematic Review of Published Studies. Eur. J. Pediatr. Surg. 2020, 31, 385–389. https://doi.org/10.1055/s-0040-1716836.
27.
Nakagawara, A.; Li, Y.; Izumi, H.; et al. Neuroblastoma. Jpn. J. Clin. Oncol. 2018, 48, 214–241. https://doi.org/10.1093/jjco/hyx176.
28.
Qiu, B.; Matthay, K.K. Advancing therapy for neuroblastoma. Nat. Rev. Clin. Oncol. 2022, 19, 515–533. https://doi.org/10.1038/s41571-022-00643-z.
29.
Zimmerman, M.W.; Liu, Y.; He, S.; et al. MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov. 2018, 8, 320–335. https://doi.org/10.1158/2159-8290.cd-17-0993.
30.
Turner, K.M.; Deshpande, V.; Beyter, D.; et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 2017, 543, 122–125. https://doi.org/10.1038/nature21356.
31.
Berbegall, A.P.; Bogen, D.; Pötschger, U.; et al. Heterogeneous MYCN amplification in neuroblastoma: A SIOP Europe Neuroblastoma Study. Br. J. Cancer 2018, 118, 1502–1512. https://doi.org/10.1038/s41416-018-0098-6.
32.
Evans, A.E.; Silber, J.H.; Shpilsky, A.; et al. Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J. Clin. Oncol. 1996, 14, 2504–2510. https://doi.org/10.1200/jco.1996.14.9.2504.
33.
Radha, G.; Lopus, M. The spontaneous remission of cancer: Current insights and therapeutic significance. Transl. Oncol. 2021, 14, 101166. https://doi.org/10.1016/j.tranon.2021.101166.
34.
D’Alessandris, N.; Santoro, A.; Arciuolo, D.; et al. What Can Trigger Spontaneous Regression of Breast Cancer? Diagnostics 2023, 13, 1224. https://doi.org/10.3390/diagnostics13071224.
35.
Cheung, N.K.V.; Dyer, M.A. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer 2013, 13, 397–411. https://doi.org/10.1038/nrc3526.
36.
Bottino, C.; Dondero, A.; Bellora, F.; et al. Natural Killer Cells and Neuroblastoma: Tumor Recognition, Escape Mechanisms, and Possible Novel Immunotherapeutic Approaches. Front. Immunol. 2014, 5, 56. https://doi.org/10.3389/fimmu.2014.00056.
37.
Yamamoto, K. Marginal Decrease in Mortality and Marked Increase in Incidence as a Result of Neuroblastoma Screening at 6 Months of Age: Cohort Study in Seven Prefectures in Japan. J. Clin. Oncol. 2002, 20, 1209–1214. https://doi.org/10.1200/jco.20.5.1209.
38.
Woods, W.G.; Tuchman, M.; Robison, L.L.; et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996, 348, 1682–1687. https://doi.org/10.1016/s0140-6736(96)06020-5.
39.
Brodeur, G.M.; Bagatell, R. Mechanisms of neuroblastoma regression. Nat. Rev. Clin. Oncol. 2014, 11, 704–713. https://doi.org/10.1038/nrclinonc.2014.168.
40.
Nuchtern, J.G.; London, W.B.; Barnewolt, C.E.; et al. A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants. Ann. Surg. 2012, 256, 573–580. https://doi.org/10.1097/sla.0b013e31826cbbbd.
41.
Alt, F.W.; Kellems, R.E.; Bertino, J.R.; et al. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol. Chem. 1978, 253, 1357–1370. https://doi.org/10.1016/s0021-9258(17)34875-5.
42.
Haber, D.A.; Schimke, R.T. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell 1981, 26, 355–362. https://doi.org/10.1016/0092-8674(81)90204-x.
43.
Hu, J.; Marincola, F.M.; Clay, E.; et al. The Perfect Storm: Viral Mimicry Meets Cancer Dark Matter. Transl. Insights 2026, 1, 3. https://doi.org/10.53941/ti.2026.100003.
44.
Nesci, S.; Marchi, S.; Hu, J.; et al. Inflammatory mitochondrial signalling and viral mimicry in cancer. J. Transl. Med. 2025, 23, 982. https://doi.org/10.1186/s12967-025-06931-3.
45.
Wang, R.; Dong, X.; Zhang, X.; et al. Exploring viral mimicry combined with epigenetics and tumor immunity: New perspectives in cancer therapy. Int. J. Biol. Sci. 2025, 21, 958–973. https://doi.org/10.7150/ijbs.103877.
46.
Lau, L.; Henderson, K.; Turkoz, A.; et al. KDM5 demethylases suppress R-loop-mediated ‘viral mimicry’ and DNA damage in breast cancer cells. eLife 2025, 14, RP106249. https://doi.org/10.7554/elife.106249.
47.
Guil, S.; Esteller, M. PRC2 Loss and DNMT Inhibition Boost Viral Mimicry in Cancer. Cancer Discov. 2022, 12, 2020–2022. https://doi.org/10.1158/2159-8290.cd-22-0733.
48.
Purohit, T.A.; Gawdzik, J.; Armstrong, E.A.; et al. Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer. Neoplasia 2026, 73, 101289. https://doi.org/10.1016/j.neo.2026.101289.
49.
Emran, A.A.; Chatterjee, A.; Rodger, E.J.; et al. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends Immunol. 2019, 40, 328–344. https://doi.org/10.1016/j.it.2019.02.004.
50.
Janin, M.; Esteller, M. Epigenetic Awakening of Viral Mimicry in Cancer. Cancer Discov. 2020, 10, 1258–1260. https://doi.org/10.1158/2159-8290.cd-20-0947.
51.
Roulois, D.; Loo Yau, H.; Singhania, R.; et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 2015, 162, 961–973. https://doi.org/10.1016/j.cell.2015.07.056.
52.
Chiappinelli, K.B.; Strissel, P.L.; Desrichard, A.; et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2015, 162, 974–986. https://doi.org/10.1016/j.cell.2015.07.011.
53.
Devasahayam Arokia Balaya, R.; Kanekar, S.; Kumar, S.; et al. Role of DEAD/DEAH-box helicases in immunity, infection and cancers. Cell Commun. Signal. 2025, 23, 292. https://doi.org/10.1186/s12964-025-02225-9.
54.
Li, S.; Huo, Y.; Fa, H.; et al. Tumour-associated dsRNA accumulation and innate immune activation: mechanistic basis and therapeutic strategies. eBioMedicine 2026, 132, 106493.
55.
Chen, R.; Zou, J.; Chen, J.; et al. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct. Target. Ther. 2025, 10, 216.
56.
Scott, D.; Elsden, J.; Pearson, A.; et al. Genes co-amplified with MYCN in neuroblastoma: Silent passengers or co-determinants of phenotype? Cancer Lett. 2003, 197, 81–86. https://doi.org/10.1016/s0304-3835(03)00086-7.
57.
Godbout, R.; Li, L.; Liu, R.Z.; et al. Role of DEAD box 1 in retinoblastoma and neuroblastoma. Future Oncol. 2007, 3, 575–587. https://doi.org/10.2217/14796694.3.5.575.
58.
Lindholm, H.T.; Chen, R.; De Carvalho, D.D. Endogenous retroelements as alarms for disruptions to cellular homeostasis. Trends Cancer 2023, 9, 55–68. https://doi.org/10.1016/j.trecan.2022.09.001.
59.
Tan, S.; Kim, S.; Kim, Y. Targeting mitochondrial RNAs enhances the efficacy of the DNA-demethylating agents. Sci. Rep. 2024, 14, 30767. https://doi.org/10.1038/s41598-024-80834-z.
60.
Rosenberg, L.; Vabret, N. Viral mimicry in cancer therapy. Trends Cancer 2025, 11, 1185–1202. https://doi.org/10.1016/j.trecan.2025.08.010.
61.
Dhir, A.; Dhir, S.; Borowski, L.S.; et al. Mitochondrial double-stranded RNA triggers antiviral signalling in humans. Nature 2018, 560, 238–242. https://doi.org/10.1038/s41586-018-0363-0.
62.
Cortesi, A.; Gandolfi, F.; Arco, F.; et al. Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer. Sci. Adv. 2024, 10, eadk5386. https://doi.org/10.1126/sciadv.adk5386.
63.
Lou, J.; Zhang, D. Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes. Exp. Hematol. Oncol. 2026, 15, 100.
64.
Fulda, S.; Lutz, W.; Schwab, M.; et al. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999, 18, 1479–1486. https://doi.org/10.1038/sj.onc.1202435.
65.
Teitz, T.; Wei, T.; Valentine, M.B.; et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000, 6, 529–535. https://doi.org/10.1038/75007.
66.
Chahine, J.J.; Davis, S.S.; Culfaci, S.; et al. Chromosome 8q24 amplification associated with human hepatocellular carcinoma predicts MYC/ZEB1/MIZ1 transcriptional regulation. Sci. Rep. 2024, 14, 24488. https://doi.org/10.1038/s41598-024-75219-1.
67.
Adan-Villaescusa, E.; Castello-Uribe, B.; Uriarte, I.; et al. Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma. Cell Rep. Med. 2026, 7, 102717. https://doi.org/10.1016/j.xcrm.2026.102717.
68.
Jiang, X.; Huang, Z.; Zhong, Y.; et al. Human endogenous retroviruses in liver cancer: A double-edged sword in tumor progression and anti-tumor immunity. Crit. Rev. Oncol. Hematol. 2026, 223, 105337. https://doi.org/10.1016/j.critrevonc.2026.105337.
69.
Taub, R.; Kirsch, I.; Morton, C.; et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. USA 1982, 79, 7837–7841. https://doi.org/10.1073/pnas.79.24.7837.
70.
Leder, P.; Battey, J.; Lenoir, G.; et al. Translocations Among Antibody Genes in Human Cancer. Science 1983, 222, 765–771. https://doi.org/10.1126/science.6356357.
71.
Rochford, R.; Cannon, M.J.; Moormann, A.M. Endemic Burkitt’s lymphoma: A polymicrobial disease? Nat. Rev. Microbiol. 2005, 3, 182–187. https://doi.org/10.1038/nrmicro1089.
72.
Thorley-Lawson, D.A.; Allday, M.J. The curious case of the tumour virus: 50 years of Burkitt’s lymphoma. Nat. Rev. Microbiol. 2008, 6, 913–924.
73.
Molyneux, E.M.; Rochford, R.; Griffin, B.; et al. Burkitt’s lymphoma. Lancet 2012, 379, 1234–1244.
74.
Bell, T.M.; Massie, A.; Ross, M.G.R.; et al. Isolation of a Reovirus from a Case of Burkitt’s Lymphoma. BMJ 1964, 1, 1212–1213. https://doi.org/10.1136/bmj.1.5392.1212.
75.
Bell, T.M.; Massie, A.; Ross, M.G.R.; et al. Further Isolations of Reovirus Type 3 from Cases of Burkitt’s Lymphoma. BMJ 1966, 1, 1514–1517. https://doi.org/10.1136/bmj.1.5502.1514.
76.
Bell, T.M.; Ross, M.G.R. Persistent Latent Infection of Human Embryonic Cells with Reovirus Type 3. Nature 1966, 212, 412–414. https://doi.org/10.1038/212412a0.
77.
Rovigatti, U.; Selli, C.; Bartoletti, R. Of Mice and Men—Viruses and Prostate Cancer: What Is the Next Step? Eur. Urol. 2010, 58, 684–686. https://doi.org/10.1016/j.eururo.2010.08.016.

Scilight Press

Author Information

Abstract

Keywords

References

Discover

Flagship Journals

Support

Company